Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Federica Elia
Institution:
Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco"
Observed institutions:
University of Catania,
Oasi Maria SS,
Policlinico Universitario di Catania,
Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco"
ORCID:
0000-0002-2449-5808
Observed ORCID:
0000-0002-2449-5808
OpenAlex ID:
A5063250983
Multiple Myeloma in 2023 Ways: From Trials to Real Life
2023
·
Manlio Fazio
, Vittorio Del Fabro
, et al.
·
Current Oncology
·
15
PDF
Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study
2023
·
Vittorio Del Fabro
, Mary Ann Di Giorgio
, et al.
·
Cancers
·
9
PDF
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy
2025
·
Concetta Conticello
, Vittorio Del Fabro
, et al.
·
Annals of Hematology
·
1
PDF
IgG-k/IgG-λ Para-Osseous Plasmacytoma Relapsed as Soft-Tissue Plasmacytoma with IgA-k Immunophenotype: A Case Report and Review of the Literature on Related Biochemical Aspects
2024
·
Manlio Fazio
, Chiara Maria Catena Sorbello
, et al.
·
Hematology Reports
·
1
PDF
Multicentric Castleman Disease and Concurrent Hematological Disorders: The Occurrence of Plasmacytoma and the Hypotheses Arising from Literature Review
2023
·
Andrea Duminuco
, Alessandra Romano
, et al.
·
Acta Haematologica
·
1
Poly (ADP-ribose) polymerase-1 (PARP-1) −410C/T polymorphism in Sicilian patients with Parkinson's disease
2016
·
Maria Grazia Salluzzo
, Filomena I. Cosentino
, et al.
·
Journal of the Neurological Sciences
·
1
Long-Term Survival with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients—A Survey from Two Italian Centers
2026
·
Vittorio Del Fabro
, Lara Gullo
, et al.
·
Diseases
PDF
Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy
2025
·
Concetta Conticello
, Vittorio Del Fabro
, et al.
·
Annals of Hematology
PDF
Effectiveness, safety, and tolerability of delayed dexamethasone, rituximab, and cyclophosphamide as first-line treatment in patients with Waldenström macroglobulinemia: data from the Sicilian Myeloma Network
2024
·
Vittorio Del Fabro
, Uros Markovic
, et al.
·
Frontiers in Hematology
PDF
Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability
2019
·
Alessandra Pompa
, Concetta Conticello
, et al.
·
Blood
Show more works
View as search
Works count:
10
Citation count:
28
H-index:
2
I10-index:
1
Year
Topic
Type